Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eflimrufusp alfa
- Development stage
- Phase 3
- Lead developer
- RemeGen
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Ophthalmic
01
Overview
Eflimrufusp alfa (RC28-E) is a recombinant fusion protein biologic developed by RemeGen Co., Ltd. It is designed as a dual-targeting decoy receptor trap that simultaneously inhibits Vascular Endothelial Growth Factor (VEGF) and Fibroblast Growth Factor 2 (FGF2). By blocking both pathways, it aims to address the complex pathophysiology of retinal vascular diseases more effectively than traditional anti-VEGF monotherapies. The drug is currently being evaluated in clinical trials for various ophthalmic conditions, including nonproliferative diabetic retinopathy (NPDR), wet age-related macular degeneration (wAMD), and diabetic macular edema (DME). It is administered via intravitreal injection to directly target the ocular environment.
- Other names
- eflimrufusp alfa
02
Targets
Beyond the preview
Go deeper on eflimrufusp alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eflimrufusp alfa.